Navigation Links
Agonist in Medical News

Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone

SOUTH SAN FRANCISCO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today announced that its right to receive from Bristol-Myers Squibb (NYSE: BMY ) a milestone payment of $5 million was triggered as a result of the acceptance of an Investigational New Drug applicat...

Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist

SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of a Phase 2 clinical trial of an orally administered niacin receptor agonist drug candidate being developed by Merck & Co., Inc., under its collaboration with Arena to t...

Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development

...omodulation, Minneapolis, Minnesota Pre-clinical development of a Parkinson's disease therapy using a glucagon-like peptide (GLP-1) receptor agonist Kevin Tomaselli, PhD, Amylin Pharmaceuticals, Inc., San Diego, California Symptomatic Approaches/Complications of Treatment ...

EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease

...nts with its nicotinic alpha-7 agonist EVP-6124. WHEN: Wednesday, July 15,...cotinic acetylcholine receptor agonist currently in development for A...uct is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials fo...

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain

...ETY INFORMATION Like other drugs with mu-opioid agonist activity, NUCYNTA(TM) is contraindicated in patien...e to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA(TM) sh...ression. Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, o...

An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market

...ts but will remain vigilant in monitoring the safety of these drugs in their patients who receive them. The report finds that as new long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA products emerge from clinical development ...

Personality May Not Predict Parkinson's

... used to treat Parkinson's disease have varying effects on creativity. The disease is thought to hurt creativity, although treatment with dopamine agonist therapy -- which reduces dopamine levels -- can boost it. The study involved people who underwent deep-brain stimulation, a surgical treatment for...

KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute

... The professional product labeling for OxyContin(R) Tablets contains the following boxed warning : WARNING: OxyContin(R) is an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine. Oxycodone can be abused in a manner similar to other opioid ...

Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents

...Japan. The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the dopamine agonist drug class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modut...

Obesity does not worsen asthma, but may reduce response to medications

...ed a 55% greater reduction in exhaled nitric oxide, a measure of inflammation. Lean patients taking a combination inhaled steroid and long-acting beta agonist increased their FEV1 by 80 more milliliters. There were no differences, however, between these patients in the number of asthma exacerbations. "The...
Agonist in Medical Technology

VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis

First Selective TLR8 Agonist to Advance for Treatment of Allergy SAN DIEGO , April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory ...

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology

First Selective TLR8 Agonist to Advance to Clinical Trials SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary end...

U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease

Requip XL Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients' "Off" Time by Nearly Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., June 13 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK ) today announced the approval of Requip(R) XL(TM) (ropini...

NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204. The single-center study, which NuRx expects to co...

UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included...

Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included...

TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, ...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

...arter as planned," said Mike Cola, President of Shire Specialty Pharmaceuticals. "When approved, INTUNIV will be the first selective alpha-2A receptor agonist for the treatment of ADHD, and will provide patients with an important new treatment option." About INTUNIV INTUNIV is being studied for...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

...level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue. "We are very pleased that Swissmedic has recognised the potential of treatment of sexual deviations with Moapar(R)," said Rolland-Yve...

More>>

Agonist in Medical Products

Plateletworks Combo-25 Kit

Description:...is required. A 1.0 cc whole blood sample is added to both a Baseline and an agonist Reagent Tube. Both tubes are run on the Ichor analyzer. Kit includes 25 ADP and 25 Collagen agonist Reagent Tubes...
Company:Helena Laboratories

Ichor Hematology Analyzer

Description:... plus platelet aggregation within five minutes. The test is simple. A fresh whole blood sample is added to both an EDTA baseline and a Collagen or ADP agonist tube. All tubes are run on the Ichor hematology analyzer. CBC, including platelet count, is available within minutes. Platelet aggregation is then cal...
Company:Helena Laboratories

Platelet Aggregation Profiler Model PAP-8E

Features:... Eight Test Channels Test Control and Patient Samples Concurrently Run Different agonist Concentrations At The Same Time Create Multi-Point Standard Curves In One Run Data Analysis With User Selected Points and Functions On Active or...
Company:Bio/Data Corporation
Agonist in Medical Dictionary

Intoxication

...... Alcoholic Intoxication /blood* Cross-Sectional Studies. Female. Gonadal ... Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare. ... Especially in old patients, intoxications (with cholinergics) should be ... ...

Innate

...f mathematical things is almost innate in us. ... Children do not give up their innate imagination, curiosity, dreaminess easily. ... The TLR5 agonist flagellin induces innate and adaptive immune responses in a ... played distinct roles in the innate response to flagellin, with the ... Defi...
Agonist in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

...ic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer. Safe Harbor Statement Statements in this press releas...

New asthma research opposes current drug treatment, says UH prof

...e of PNAS in February. The timely release of this study comes on the heels of the FDA considering a renewed look at the use of long-acting beta agonist drugs (LABAs) at least those used alone, without a steroidal component for the management of asthma symptoms. In an FDA report released in December...

TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims

...any with a novel molecule that may play an important role and have broad application in the treatment of cancer." VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggest...

Mechanism explains link between apolipoprotein E and Alzheimer's disease

...n. Activation of liver X receptors (LXRs) to enhance expression of lipidated ApoE significantly facilitated A? degradation. Importantly, use of an LXR agonist to increase lipidated forms of ApoE in a mouse model of AD resulted in reduced A? plaque levels and an improvement in contextual memory. The resul...

New treatment mechanisms for schizophrenia

...have traditionally been very effective with fewer side effects than chronic agonist treatment. He adds, These data support the conclusion that NAAG peptidase ...s (7 nAChRs) in the mouse brain, and that the novel 7 nAChR agonist SSR180711 could ameliorate PCP-induced cognitive deficits in mice. Accordi...

The endocannabinoids: Functional roles and therapeutic opportunities

...istration of 2-AG improved a neurological score, activity and cognitive function (Avraham et al., 2006). Activation of the CB2 receptor by a selective agonist also improved the neurological score. The authors concluded that the endocannabinoid system may play an important role in the pathogenesis of hepatic ...

How does the opioid system control pain, reward and addictive behavior?

...should greatly help to further our knowledge of the general mechanisms that underlie addiction. Opiate addicts, who mainly abuse the mu-opioid agonist heroin, present a high incidence of depressive disorders that seem to contribute to the maintenance of the addictive state. Also, the treatment of chr...

JCI table of contents: Aug. 9, 2007

...effects on behavior were associated with decreased signaling in the hypothalamus through a protein known as PPAR-alpha. Administration of a PPAR-alpha agonist into the hypothalamus increased the amount mice lacking FAS specifically in the beta-islet cells and in the hypothalamus ate but did not increase the ...

OHSU lab finds meth receptor that could lead to therapy

... who also directed the groundbreaking research. "In our most recent article, we provide clear evidence that methamphetamine is a full and potent agonist of TAAR1. In other words, TAAR1 has the necessary features to be considered a real target of methamphetamine and amphetamine in rodents and probably h...

Insulin receptor stops progression of Alzheimer's disease

...sts prevent several components of neurodegeneration and preserve learning and memory in rats with induced Alzheimer's disease (AD). They found that an agonist for PPAR delta, a receptor that is abundant in the brain, had the most overall benefit. "This raises the possibility that you can treat patients wi...
Agonist in Biological Technology

TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

LA JOLLA, Calif., March 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren's syndrome. The company is conducting a randomized, d...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatmen...

Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist

LUGANO, Switzerland, November 27 /PRNewswire/ -- Helsinn Healthcare's Top management today announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a...

Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist

-- Data Presented at 20th EORTC-NCI-AACR Symposium -- SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane catio...

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration

...ly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection. Prelimina...

VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ

... property related to our product candidates; our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; our ability to obtain strategic opportunities to partner and collaborate with large biote...

EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease

...imer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced...o's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction...uct is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials f...

EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator

...ent focus on Alzheimer's disease , Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...ng towards clinical development of an oral form of the peptide hormone drug leuprolide using the LPM(TM) technology. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone (GnRh) that is used in treatment of endometriosis in women and prostate cancer in men. In preclinical studies in rat...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

...mcg or 150 mcg corifollitropin alfa in a long GnRH agonist protocol was able to support multifollicular devel...-regulated with daily injections of 0.1 mg of GnRH agonist (starting on cycle day 21). Ovarian stimulation wa...lot study with corifollitropin alfa in a long GnRH agonist protocol indicates the development of a large coho...
Agonist in Biological Products

Calcium Flux Agonist Chip, 4-Sipper (coated) from Caliper Life Sciences

Description: Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Company:Caliper Life Sciences
Agonist in Biological Dictionary

Photolysis

...y articles plus many other academic journal articles, magazine articles & newsp... in the inactive form, flash photolysis producing a pulse of agonist at a known ... intensity for photolysis can be achieved in light spots large enough to encompass an ... Photodissociation summary with 6 pages of...
Other Tags
(Date:7/28/2014)... July 28, 2014 Quincy Bioscience, makers ... is pleased to announce the release of the fourth ... president and co-founder Mark Underwood. , The Brain Health ... offering useful techniques for readers to improve memory and ... unavoidable conclusion, The Brain Health Guide provides ways to ...
(Date:7/28/2014)... procedure to treat severe chronic migraine headaches led to ... time in patients treated at Massachusetts General Hospital (MGH). ... Reconstructive Surgery report that more than half of 35 ... whom had headaches associated with compression of craniofacial nerves ... The team,s paper has received advance online publication in ...
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
(Date:7/28/2014)... runners are far more likely to die of heat ... new study. The researchers pointed out that ... actually 10 times more likely to develop severe and ... of a young and apparently healthy person due to ... gets a lot more media attention. "This research ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift this ... PC that will benefit each community we serve for ... The HBWS group is among the Foundation’s largest physician ... donations. Through their latest gift, they will be one ... Classic for the next 6 years; provide state-of-the-art technology ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2
(Date:7/28/2014)... Rice University researchers are using magnetic beads and ... can be used as microscale models for polymer macromolecules. ... introduced as theory in the 1950s, can be made ... be of interest to materials scientists who study the ... Rice chemical and biomolecular engineer Sibani Lisa Biswal and ...
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
(Date:7/28/2014)... explorer Roald Amundsen became the first man to reach ... 100 years later, an international team of scientists led ... have proven that air pollution from industrial activities arrived ... collected from widely spaced locations around the Antarctic continent, ... accurate and precise reconstruction to date of lead pollution ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
Other Contents